B-MS expands R&D presence in India
US pharmaceutical major Bristol-Myers Squibb says that it is expanding its R&D capabilities in India. The increase is an integral part of the company's overall R&D global strategy of accessing top-talent around the world in support of its goal of achieving sustainable, cost-effective growth, says B-MS.
The US group will significantly increase the scope of its existing relationship with Indian firm Biocon to further develop integrated capabilities in India in medicinal chemistry, biology, drug metabolism and pharmaceutical development. Under the terms of the agreement Biocon, through its subsidiary Syngene International, will work with B-MS to establish a research facility in Bangalore that could ultimately house more than 400 scientists to help advance B-MS' discovery and early drug development, the firm notes.
Expands deal with Accenture
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze